Bicara Therapeutics (BCAX) Stock Price, News & Analysis

Company Overview

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder. Both programs are supported by preclinical validation and early-stage clinical data demonstrating target engagement and potential improvements in mood and social functioning. Bicara’s pipeline leverages translational biomarkers to guide dose selection and patient stratification in ongoing studies.

Founded in 2020 and headquartered in Cambridge, Massachusetts, Bicara Therapeutics completed its initial public offering on the Nasdaq in 2021. The company’s management team brings together experienced leaders from neuroscience, endocrinology and pharmaceutical development. Bicara also collaborates with academic centers and contract research organizations to accelerate its clinical programs and expand the understanding of neurohormone mechanisms in human disease.

Looking ahead, Bicara plans to advance its lead candidates through proof-of-concept studies while exploring additional neurohormone targets for depression, anxiety and other central nervous system indications. By combining peptide chemistry with intranasal formulations, the company aims to address significant unmet needs in mental health and to establish a new class of therapeutics with improved efficacy and tolerability profiles.

Key Stats

• Today's Range: $18.45 to $19.24
• 50-Day Range: $9.99 to $18.81
• 52-Week Range: $7.80 to $28.09
• Volume: 800,808 shs
• Average Volume: 583,027 shs
• Market Capitalization: $1.02 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $31.86
• Consensus Rating: Moderate Buy

Bicara Therapeutics Stock Analysis - MarketRank™

Bicara Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 660th out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Bicara Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Bicara Therapeutics has a consensus price target of $31.86, representing about 70.5% upside from its current price of $18.68.

Amount of Analyst Coverage

Bicara Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Bicara Therapeutics are expected to grow in the coming year, from ($2.59) to ($1.74) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bicara Therapeutics is -5.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bicara Therapeutics is -5.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bicara Therapeutics has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.64% of the float of Bicara Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Bicara Therapeutics has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Bicara Therapeutics has recently decreased by 3.70%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bicara Therapeutics does not currently pay a dividend.

Dividend Growth

Bicara Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.64% of the float of Bicara Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Bicara Therapeutics has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Bicara Therapeutics has recently decreased by 3.70%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.26

News Sentiment

Bicara Therapeutics has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 23 news articles for Bicara Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 3 people have searched for BCAX on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

MarketBeat Follows

1 people have added Bicara Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Bicara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,455,012.00 in company stock.

Percentage Held by Insiders

15.50% of the stock of Bicara Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

BCAX Stock Analysis - Frequently Asked Questions

How have BCAX shares performed this year?

Bicara Therapeutics' stock was trading at $17.42 at the beginning of the year. Since then, BCAX stock has increased by 7.2% and is now trading at $18.68.

How were Bicara Therapeutics' earnings last quarter?

Bicara Therapeutics Inc. (NASDAQ:BCAX) announced its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.04.

When did Bicara Therapeutics IPO?

Bicara Therapeutics (BCAX) raised $315 million in an initial public offering on Friday, September 13th 2024. The company issued 17,500,000 shares at $18.00 per share.

Who are Bicara Therapeutics' major shareholders?

Bicara Therapeutics' top institutional shareholders include Avanza Fonder AB (0.02%). Insiders that own company stock include Ra Capital Management, LP, Claire Mazumdar, Ryan Cohlhepp, Ivan Hyep and David Raben.
View institutional ownership trends.

How do I buy shares of Bicara Therapeutics?

Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/12/2025
• Today: 10/16/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BCAX
• Previous Symbol: NASDAQ:BCAX
• CIK: 2023658
• Web: www.bicara.com
• Phone: (617) 468-4219
• Fax: N/A
• Employees: 32
• Year Founded: 2020

Price Target and Rating

• Average Price Target for Bicara Therapeutics: $31.86
• High Price Target: $48.00
• Low Price Target: $8.00
• Potential Upside/Downside: +69.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$68 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -21.67%
• Return on Assets: -20.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 25.80
• Quick Ratio: 25.80

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.04 per share
• Price / Book: 2.08

Miscellaneous

• Outstanding Shares: 54,610,000
• Free Float: 46,147,000
• Market Cap: $1.03 billion
• Optionable: N/A
• Beta: N/A